OVERVIEW

Renal disease in Obesity and Diabetes Advances in Pathogenesis and Therapeutics is organized by European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and would be held during Nov 24 - 25, 2017 at Hotel Novotel Lisboa, Lisbon, Lisboa, Portugal. The target audience for this medical event for Endocrinologists and Nephrologists.

Conference Description :
• Renal lipotoxicity in diabetes and obesity.
• Inflammation in diabetic nephropathy.
• Insulin resistance and renal disease.
• New insight in the pathogenesis of Diabetic Nephropathy.
• Animal models of renal disease in obesity and diabetes.
• Pathogenesis of glomerular hyperfiltration.
• The ENBiBA project : Renal histology in patients with T2DM, metabolic syndrome and obesity without proteinuria.
• Metabolic Syndrome, obesity and beta-cell dysfunction.
• Kidney pancreas transplantation - the solution.
• Weight reduction in patients with CKD : the Nutritionist point of view.
• Weight reduction to prevent renal disease in diabetes - CRESO I and II.
• Bariatric surgery to prevent renal disease.
• Childhood obesity and its impacts on the kidney.
• Dual RAS blockade in diabetic nephropathy and obesity.
• SGLT2 for renoprotection in T2DM.
• Experimental treatments for diabetic renal disease.

Additional details will be posted as soon as they are available.

KEY DATES

Event Start Date
24 Nov, 2017
Event Start Date
Event End Date
25 Nov, 2017
Event End Date

SPECIALITIES

Endocrinology, Metabolism and DiabetesNephrology

VENUE

Hotel Novotel Lisboa
Avenida Jose Malhoa 1 1A
Want us to help plan your travel ?
Hotels
Flights
Rides

RELATED CONFERENCES & LIVE WEBINARS

Family Medicine: Common Challenges in Internal Medicine, Geriatrics, and Nephrology - Hybrid Event
May 15 - 18, 2023 | Sarasota, Florida,...
Family Medicine
20 AMA PRA Category 1 Credit™
More actions
US$699
Family Medicine: Common Challenges in Internal Medicine, Geriatrics, and Nephrology - In-person Event
May 15 - 18, 2023 | Sarasota, Florida,...
Internal Medicine
20 AMA PRA Category 1 Credit™
More actions
US$1,025